Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
P/B ratio for Reneo Pharmaceuticals, Inc. (RPHM)
P/B ratio as of 2023: 0.55
According to Reneo Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.55. At the end of 2022 the company had a P/B ratio of 0.57.
P/B ratio history for Reneo Pharmaceuticals, Inc. from 2001 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.55 |
| 2022 | 0.57 |
| 2021 | 1.05 |
| 2020 | -8.62 |
| 2019 | -5.05 |
| 2001 | 0.00 |